277 related articles for article (PubMed ID: 34146720)
1. MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies.
Taylor HB; Klaeger S; Clauser KR; Sarkizova S; Weingarten-Gabbay S; Graham DB; Carr SA; Abelin JG
Mol Cell Proteomics; 2021; 20():100116. PubMed ID: 34146720
[TBL] [Abstract][Full Text] [Related]
2. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
3. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
4. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
[TBL] [Abstract][Full Text] [Related]
5. The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.
Vizcaíno JA; Kubiniok P; Kovalchik KA; Ma Q; Duquette JD; Mongrain I; Deutsch EW; Peters B; Sette A; Sirois I; Caron E
Mol Cell Proteomics; 2020 Jan; 19(1):31-49. PubMed ID: 31744855
[TBL] [Abstract][Full Text] [Related]
6. Challenges and opportunities in analyzing and modeling peptide presentation by HLA-II proteins.
ElAbd H; Bacher P; Tholey A; Lenz TL; Franke A
Front Immunol; 2023; 14():1107266. PubMed ID: 37063883
[TBL] [Abstract][Full Text] [Related]
7. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.
Álvaro-Benito M; Morrison E; Abualrous ET; Kuropka B; Freund C
Front Immunol; 2018; 9():872. PubMed ID: 29774024
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
[TBL] [Abstract][Full Text] [Related]
9. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
10. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
ElAbd H; Franke A
Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
[TBL] [Abstract][Full Text] [Related]
11. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells.
Parker R; Partridge T; Wormald C; Kawahara R; Stalls V; Aggelakopoulou M; Parker J; Powell Doherty R; Ariosa Morejon Y; Lee E; Saunders K; Haynes BF; Acharya P; Thaysen-Andersen M; Borrow P; Ternette N
Cell Rep; 2021 May; 35(8):109179. PubMed ID: 34004174
[TBL] [Abstract][Full Text] [Related]
12. HLA Class II Presentation Is Specifically Altered at Elevated Temperatures in the B-Lymphoblastic Cell Line JY.
Demmers LC; Wu W; Heck AJR
Mol Cell Proteomics; 2021; 20():100089. PubMed ID: 33933681
[TBL] [Abstract][Full Text] [Related]
13. Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.
God JM; Zhao D; Cameron CA; Amria S; Bethard JR; Haque A
Immunology; 2014 Jul; 142(3):492-505. PubMed ID: 24628049
[TBL] [Abstract][Full Text] [Related]
14. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
16. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens.
Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS
AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848
[TBL] [Abstract][Full Text] [Related]
17. Predicting HLA class II antigen presentation through integrated deep learning.
Chen B; Khodadoust MS; Olsson N; Wagar LE; Fast E; Liu CL; Muftuoglu Y; Sworder BJ; Diehn M; Levy R; Davis MM; Elias JE; Altman RB; Alizadeh AA
Nat Biotechnol; 2019 Nov; 37(11):1332-1343. PubMed ID: 31611695
[TBL] [Abstract][Full Text] [Related]
18. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
Front Immunol; 2020; 11():1981. PubMed ID: 32983136
[TBL] [Abstract][Full Text] [Related]
19. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
[TBL] [Abstract][Full Text] [Related]
20. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
